The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Soliddd, an optical and vision technology company, will debut the beta headset version of its virtual reality smart glasses ...

Soliddd Corp., a New York City-based optical and vision technology company, introduced its SolidddVision smart glasses ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, ...

EyeFortin is intricately fabricated to support strong vision and to promote healthy functioning of the eyes. It contains ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMDOpthea management to present in New York City on Tuesday, January ...

New research from the Guangdong Academy of Medical Sciences has found that certain eye conditions, like age-related macular ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

CES 2025 is just around the corner, and our favorite companies are showing off their latest and greatest tech early. One of those companies is Solidd.

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.